Ignite Creation Date:
2025-12-24 @ 8:00 PM
Ignite Modification Date:
2025-12-28 @ 12:43 AM
Study NCT ID:
NCT01729104
Status:
TERMINATED
Last Update Posted:
2019-10-22
First Post:
2012-11-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-04-25
Start Date Type:
ACTUAL
Primary Completion Date:
2018-10-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-10-03
Completion Date Type:
ACTUAL
First Submit Date:
2012-11-09
First Submit QC Date:
None
Study First Post Date:
2012-11-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-10-18
Last Update Post Date:
2019-10-22
Last Update Post Date Type:
ACTUAL